Skip to main content
Clinical Trials/NCT05306821
NCT05306821RecruitingNot Applicable

Effectiveness of Interventions for Hospital Medical Thromboprophylaxis: a Bicentric Swiss Quality-improvement Study

Marc Blondon2 sites in 1 country600 target enrollmentStarted: September 1, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
600
Locations
2
Primary Endpoint
Proportion of patients with an adequate thromboprophylaxis

Study Overview

Brief Summary

The primary objective is to evaluate and compare the short-term and medicum-term effectiveness of 2 types of interventions in 2 different hospitals to improve the adequacy of hospital thromboprophylaxis among acute medical inpatients.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •acute medical inpatients hospitalized at the Geneva University Hospitals or the Lugano Regional Hospitals

Exclusion Criteria

  • •patients already on therapeutic anticoagulation
  • •patients with an estimated life expectancy of <3 months
  • •pregnancy
  • •patients hospitalized for COVID-19

Arms & Interventions

Implementation of an electronic tool for risk stratification and thromboprophylaxis prescription

Experimental

Intervention: Educative sessions (Other)

Implementation of educative sessions and pocket cards for thromboprophylaxis

Experimental

Intervention: Pocket card (Other)

Implementation of educative sessions and pocket cards for thromboprophylaxis

Experimental

Intervention: Educative sessions (Other)

Implementation of an electronic tool for risk stratification and thromboprophylaxis prescription

Experimental

Intervention: Comprehensive electronic tool in the electronic medical chart (Other)

Outcomes

Primary Outcomes

Proportion of patients with an adequate thromboprophylaxis

Time Frame: 90 days

Secondary Outcomes

  • Incidence of major bleeding(90 days)
  • Incidence of venous thromboembolism(90 days)

Investigators

Sponsor
Marc Blondon
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Marc Blondon

Principal Investigator

University Hospital, Geneva

Study Sites (2)

Loading locations...

Similar Trials